Aligos Therapeutics, Inc. cash flow to debt ratio of -1.57K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Aligos Therapeutics, Inc.'s free cash flow has decreased 2.56% from $-80.87M last year to $-82.94M, signaling decreasing performance

Aligos Therapeutics, Inc.'s debt to equity ratio is 0.11, which means that the company's assets are healthy financed, signaling financial stability.

Aligos Therapeutics, Inc.'s debt has increased relative to shareholder equity from -0.29 last year to 0.11 today, signaling weakened financials

Aligos Therapeutics, Inc. has a net cash position, so leverage is healthy.

Aligos Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Aligos Therapeutics, Inc.'s profit margin has increased (-92.75%) in the last year from -3.33K% to -241.01%, signaling increasing performance

Aligos Therapeutics, Inc.'s short-term assets of $82.86M exceed its short-term liabilities of $21.23M

Aligos Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Aligos Therapeutics, Inc.'s return on equity of -160.72%, is lower than 15.00%, indicating bad performance

Aligos Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Aligos Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Aligos Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Aligos Therapeutics, Inc. has negative free cash flow, indicating cash burn

Aligos Therapeutics, Inc.'s yearly earnings has increased -81.56% since last year from $-131.21M to $-24.19M, signaling increasing performance

Aligos Therapeutics, Inc.'s yearly revenue has decreased 100.00% since last year from $3.94M to $0.00, signaling decreasing performance

ROIC -191.73% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Aligos Therapeutics, Inc.'s 3-year revenue CAGR of -46.03% is negative, indicating declining revenue over the past 3 years

Aligos Therapeutics, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Aligos Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Aligos Therapeutics, Inc. has insufficient data to evaluate this check.

Aligos Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aligos Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Aligos Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Aligos Therapeutics, Inc. has insufficient data to evaluate this check.

Aligos Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aligos Therapeutics, Inc. has a price-to-book ratio of 2.50x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Aligos Therapeutics, Inc. has a price-to-sales ratio of 2.53x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue